Antimicrobial Agents

Principles and Practice of Pediatric Infectious Diseases, Fourth Edition

Volumn , Issue , 2012, Pages 1453-1484.e5

  Bradley, John S ^a,b   Sauberan, Jason B ^c,d  

^a University of California School of Medicine   (United States)

^b RADY CHILDREN'S HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UCSD MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84966771357     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4377-2702-9.00294-4     Document Type: Chapter

References (208)

1. TJ Silhavy, D Kahne and S Walker (2010) The bacterial cell envelope. Cold Spring Harb Perspect Biol 2 a000414
2. AL Koch (2003) Bacterial wall as target for attack: past, present, and future research. Clin Microbiol Rev 16 673-687.
3. MA Kohanski, DJ Dwyer and JJ Collins (2010) How antibiotics kill bacteria: from targets to networks. Nat Rev Microbiol 8 423-435.
4. LL Silver (2007) Multi-targeting by monotherapeutic antibacterials. Nat Rev Drug Discov 6 41-55.
5. LL Silver (2003) Novel inhibitors of bacterial cell wall synthesis. Curr Opin Microbiol 6 431-438.
6. W Vollmer and SJ Seligman (2010) Architecture of peptidoglycan: more data and more models. Trends Microbiol 18 59-66.
7. F Van Bambeke, Y Van Laethem, P Courvalin, et al. (2004) Glycopeptide antibiotics: from conventional molecules to new derivatives. Drugs 64 913-936.
8. AH Katz and CE Caufield (2003) Structure-based design approaches to cell wall biosynthesis inhibitors. Curr Pharm Des 9 857-866.
9. H Eagle (1949) The effect of the size of the inoculum and the age of the infection on the curative dose of penicillin in experimental infections with streptococci, pneumococci, and Treponema pallidum. J Exp Med 90 595-607.
10. K Bush (2010) Bench-to-bedside review: The role of beta-lactamases in antibiotic-resistant Gram-negative infections. Crit Care 14 224.
11. DA Rowe-Magnus, AM Guerout, P Ploncard, et al. (2001) The evolutionary history of chromosomal super-integrons provides an ancestry for multiresistant integrons. Proc Natl Acad Sci USA 98 652-657.
12. MH Macris, N Hartman, B Murray, et al. (1998) Studies of the continuing susceptibility of group A streptococcal strains to penicillin during eight decades. Pediatr Infect Dis J 17 377-381.
13. EL Kaplan and DR Johnson (2001) Unexplained reduced microbiological efficacy of intramuscular benzathine penicillin G and of oral penicillin V in eradication of group a streptococci from children with acute pharyngitis. Pediatrics 108 1180-1186.
14. Nelson JD. Personal communication 1998.
15. GA Jacoby (2009) AmpC beta-lactamases. Clin Microbiol Rev 22 161-182.
16. DL Paterson and RA Bonomo (2005) Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 18 657-686.
17. CC John (1994) Treatment failure with use of a third-generation cephalosporin for penicillin-resistant pneumococcal meningitis: case report and review. Clin Infect Dis 18 188-193.
18. JS Bradley and JD Connor (1991) Ceftriaxone failure in meningitis caused by Streptococcus pneumoniae with reduced susceptibility to beta-lactam antibiotics. Pediatr Infect Dis J 10 871-873.
19. AD Tice, SJ Rehm, JR Dalovisio, et al. (2004) Practice guidelines for outpatient parenteral antimicrobial therapy. IDSA guidelines. Clin Infect Dis 38 1651-1672.
20. A Endimiani, F Perez and RA Bonomo (2008) Cefepime: a reappraisal in an era of increasing antimicrobial resistance. Expert Rev Anti Infect Ther 6 805-824.
21. WT Hughes, D Armstrong, GP Bodey, et al. (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34 730-751.
22. AC Arrieta and JS Bradley (2001) Empiric use of cefepime in the treatment of serious urinary tract infections in children. Pediatr Infect Dis J 20 350-355.
23. JS Bradley and A Arrieta (2001) Empiric use of cefepime in the treatment of lower respiratory tract infections in children. Pediatr Infect Dis J 20 343-349.
24. MM Mustafa, L Carlson, I Tkaczewski, et al. (2001) Comparative study of cefepime versus ceftazidime in the empiric treatment of pediatric cancer patients with fever and neutropenia. Pediatr Infect Dis J 20 362-369.
25. K Bush, M Heep, MJ Macielag, et al. (2007) Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy. Expert Opin Investig Drugs 16 419-429.
26. GG Zhanel, R Wiebe, L Dilay, et al. (2007) Comparative review of the carbapenems. Drugs 67 1027-1052.
27. VK Wong, HT Wright Jr, LA Ross, et al. (1991) Imipenem/cilastatin treatment of bacterial meningitis in children. Pediatr Infect Dis J 10 122-125.
28. DP Nicolau (2008) Carbapenems: a potent class of antibiotics. Expert Opin Pharmacother 9 23-37.
29. GD Overturf (2010) Carbapenemases: a brief review for pediatric infectious disease specialists. Pediatr Infect Dis J 29 68-70.
30. DH Johnson and BA Cunha (1995) Aztreonam. Med Clin North Am 79 733-743.
31. W Dehority (2010) Use of vancomycin in pediatrics. Pediatr Infect Dis J 29 462-464.
32. JS Bradley (2010) Community-associated methicillin-resistant Staphylococcus aureus. JS Bradley, JD Nelson,(Eds) 2010–2011 Nelson's Pocket Book of Pediatric Antimicrobial Therapy 18th ed Elk Grove Village, IL: American Academy of Peditrics 11-13.
33. A Zirakzadeh and R Patel (2005) Epidemiology and mechanisms of glycopeptide resistance in enterococci. Curr Opin Infect Dis 18 507-512.
34. BE Murray (2000) Vancomycin-resistant enterococcal infections. N Engl J Med 342 710-721.
35. SL Rong and SN Leonard (2010) Heterogeneous vancomycin resistance in Staphylococcus aureus: a review of epidemiology, diagnosis, and clinical significance. Ann Pharmacother 44 844-850.
36. PC Appelbaum (2007) Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents 30 398-408.
37. SE Cosgrove, KC Carroll and TM Perl (2004) Staphylococcus aureus with reduced susceptibility to vancomycin. Clin Infect Dis 39 539-545.
38. PC Appelbaum and B Bozdogan (2004) Vancomycin resistance in Staphylococcus aureus. Clin Lab Med 24 381-402.
39. LK Hidayat, DI Hsu, R Quist, et al. (2006) High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 166 2138-2144.
40. MJ Rybak, BM Lomaestro, JC Rotschafer, et al. (2009) Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 49 325-327.
41. GG Zhanel, D Calic, F Schweizer, et al. (2010) New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs 70 859-886.
42. American Academy of Pediatrics (2009) Pneumococcal infections. LK Pickering, CJ Baker, DW Kimberlin, SS Long,(Eds) Red Book: 2009 Report of the Committee on Infectious Diseases 28th ed Elk Grove Village, IL: American Academy of Pediatrics 524-535.
43. SH Cohen, DN Gerding, S Johnson, et al. (2010) Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 31 431-455.
44. C Kosmidis and DP Levine (2010) Daptomycin: pharmacology and clinical use. Expert Opin Pharmacother 11 615-625.
45. CF Carpenter and HF Chambers (2004) Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis 38 994-1000.
46. SM Abdel-Rahman, DP Benziger, RF Jacobs, et al. (2008) Single-dose pharmacokinetics of daptomycin in children with suspected or proved gram-positive infections. Pediatr Infect Dis J 27 330-334.
47. M Cohen-Wolkowiez, PB Smith, DK Benjamin Jr, et al. (2008) Daptomycin use in infants: report of two cases with peak and trough drug concentrations. J Perinatol 28 233-234.
48. MI Ardura, A Mejias, KS Katz, et al. (2007) Daptomycin therapy for invasive Gram-positive bacterial infections in children. Pediatr Infect Dis J 26 1128-1132.
49. VG Fowler Jr, HW Boucher, GR Corey, et al. (2006) Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 355 653-665.
50. ED Hermsen, CJ Sullivan and JC Rotschafer (2003) Polymyxins: pharmacology, pharmacokinetics, pharmacodynamics, and clinical applications. Infect Dis Clin North Am 17 545-562.
51. ME Falagas and SK Kasiakou (2005) Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 40 1333-1341.
52. MD Reed, RC Stern, MA O’Riordan, et al. (2001) The pharmacokinetics of colistin in patients with cystic fibrosis. J Clin Pharmacol 41 645-654.
53. AS Michalopoulos and DC Karatza (2010) Multidrug-resistant Gram-negative infections: the use of colistin. Expert Rev Anti Infect Ther 8 1009-1017.
54. E Iosifidis, C Antachopoulos, M Ioannidou, et al. (2010) Colistin administration to pediatric and neonatal patients. Eur J Pediatr 169 867-874.
55. ME Falagas, EK Vouloumanou and PI Rafailidis (2009) Systemic colistin use in children without cystic fibrosis: a systematic review of the literature. Int J Antimicrob Agents 33 503 e1–503 e13
56. A Michalopoulos and E Papadakis (2010) Inhaled anti-infective agents: emphasis on colistin. Infection 38 81-88.
57. MS Brochet, AC McDuff, JF Bussieres, et al. (2007) Comparative efficacy of two doses of nebulized colistimethate in the eradication of Pseudomonas aeruginosa in children with cystic fibrosis. Can Respir J 14 473-479.
58. F Ratjen, E Rietschel, D Kasel, et al. (2006) Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J Antimicrob Chemother 57 306-311.
59. D Bulkley, CA Innis, G Blaha, et al. (2010) Revisiting the structures of several antibiotics bound to the bacterial ribosome. Proc Natl Acad Sci USA 107 17158-17163.
60. A Bashan and A Yonath (2008) Correlating ribosome function with high-resolution structures. Trends Microbiol 16 326-335.
61. A Yonath (2005) Ribosomal crystallography: peptide bond formation, chaperone assistance and antibiotics activity. Mol Cells 20 1-16.
62. AS Mankin (2008) Macrolide myths. Curr Opin Microbiol 11 414-421.
63. RC Goldman and F Scaglione (2004) The macrolide-bacterium interaction and its biological basis. Curr Drug Targets Infect Disord 4 241-260.
64. E Rubinstein (2001) Comparative safety of the different macrolides. Int J Antimicrob Agents 18(Suppl 1), S71-S76.
65. MC Roberts (2008) Update on macrolide-lincosamide-streptogramin, ketolide, and oxazolidinone resistance genes. FEMS Microbiol Lett 282 147-159.
66. F Franceschi, Z Kanyo, EC Sherer, et al. (2004) Macrolide resistance from the ribosome perspective. Curr Drug Targets Infect Disord 4 177-191.
67. R Leclercq (2002) Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin Infect Dis 34 482-492.
68. SD Feighner, CP Tan, KK McKee, et al. (1999) Receptor for motilin identified in the human gastrointestinal system. Science 284 2184-2188.
69. JM Zuckerman (2004) Macrolides and ketolides: azithromycin, clarithromycin, telithromycin. Infect Dis Clin North Am 18 621-649. xi-
70. American Society of Health-Systems Pharmacists (2009) Macrolides. AHFS Drug Information 2009 Bethesda, MD: American Society of Health-Systems Pharmacists, Inc. 226-275.
71. T Tiwari, TV Murphy and J Moran (2005) Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis: 2005 CDC Guidelines. MMWR Recomm Rep 54(RR-14), 1-16.
72. CG Mabanta, GS Pryhuber, GA Weinberg, et al. (2003) Erythromycin for the prevention of chronic lung disease in intubated preterm infants at risk for, or colonized or infected with Ureaplasma urealyticum. Cochrane Database Syst Rev CD003744
73. DE Griffith, T Aksamit, BA Brown-Elliott, et al. (2007) An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 175 367-416.
74. KE McColl (2010) Clinical practice. Helicobacter pylori infection. N Engl J Med 362 1597-1604.
75. R Khurana, L Fischbach, N Chiba, et al. (2005) An update on anti-Helicobacter pylori treatment in children. Can J Gastroenterol 19 441-445.
76. A Arguedas, P Emparanza, RH Schwartz, et al. (2005) A randomized, multicenter, double blind, double dummy trial of single dose azithromycin versus high dose amoxicillin for treatment of uncomplicated acute otitis media. Pediatr Infect Dis J 24 153-161.
77. JO Klein and UB Schaad (2004) Use of azithromycin in the treatment of acute otitis media and tonsillopharyngitis: summary and conclusions. Pediatr Infect Dis J 23 S140-S141.
78. CH von Konig (2005) Use of antibiotics in the prevention and treatment of pertussis. Pediatr Infect Dis J 24 S66-S68.
79. KA Workowski and SM Berman (2006) Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 55 1-94.
80. LM Mofenson, MT Brady, SP Danner, et al. (2009) Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm Rep 58(RR-11), 1-166.
81. HL DuPont (2007) Therapy for and prevention of traveler's diarrhea. Clin Infect Dis 45(Suppl 1), S78-S84.
82. RW Frenck Jr, A Mansour, I Nakhla, et al. (2004) Short-course azithromycin for the treatment of uncomplicated typhoid fever in children and adolescents. Clin Infect Dis 38 951-957.
83. M O’Ryan, V Prado and LK Pickering (2005) A millennium update on pediatric diarrheal illness in the developing world. Semin Pediatr Infect Dis 16 125-136.
84. JW Bass, BC Freitas, AD Freitas, et al. (1998) Prospective randomized double blind placebo-controlled evaluation of azithromycin for treatment of cat-scratch disease. Pediatr Infect Dis J 17 447-452.
85. I Chopra and M Roberts (2001) Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 65 232-260.
86. DL Lafontaine and D Tollervey (2001) The function and synthesis of ribosomes. Nat Rev Mol Cell Biol 2 514-520.
87. DE Brodersen, WM Clemons Jr, AP Carter, et al. (2000) The structural basis for the action of the antibiotics tetracycline, pactamycin, and hygromycin B on the 30S ribosomal subunit. Cell 103 1143-1154.
88. MC Roberts (2005) Update on acquired tetracycline resistance genes. FEMS Microbiol Lett 245 195-203.
89. B Volovitz, R Shkap, J Amir, et al. (2007) Absence of tooth staining with doxycycline treatment in young children. Clin Pediatr (Phila) 46 121-126.
90. ER Grossman, A Walchek and H Freedman (1971) Tetracyclines and permanent teeth: the relation between dose and tooth color. Pediatrics 47 567-570.
91. BD Schmitt (1968) Indications for tetracycline in pediatrics. Pediatrics 42 213.
92. American Academy of Pediatrics (2009) Tetracyclines. LK Pickering, CJ Baker, DW Kimberlin, SS Long,(Eds) Red Book: 2009 Report of the Committee on Infectious Diseases Elk Grove Village: American Academy of Pediatrics 739.
93. JJ Ruhe, T Monson, RW Bradsher, et al. (2005) Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literature. Clin Infect Dis 40 1429-1434.
94. GG Zhanel, K Homenuik, K Nichol, et al. (2004) The glycylcyclines: a comparative review with the tetracyclines. Drugs 64 63-88.
95. F Schlunzen, R Zarivach, J Harms, et al. (2001) Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature 413 814-821.
96. J Spizek and T Rezanka (2004) Lincomycin, clindamycin and their applications. Appl Microbiol Biotechnol 64 455-464.
97. CR Woods (2009) Macrolide-inducible resistance to clindamycin and the D-test. Pediatr Infect Dis J 28 1115-1118.
98. WL Hand and NL King-Thompson (1990) Uptake of antibiotics by human polymorphonuclear leukocyte cytoplasts. Antimicrob Agents Chemother 34 1189-1193.
99. JS Solomkin, JE Mazuski, JS Bradley, et al. (2010) Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 50 133-164.
100. KE Aldridge, D Ashcraft, M O’Brien, et al. (2003) Bacteremia due to Bacteroides fragilis group: distribution of species, beta-lactamase production, and antimicrobial susceptibility patterns. Antimicrob Agents Chemother 47 148-153.
101. GH McCracken Jr (1995) Emergence of resistant Streptococcus pneumoniae: a problem in pediatrics. Pediatr Infect Dis J 14 424-428.
102. SL Kaplan (2005) Treatment of community-associated methicillin-resistant Staphylococcus aureus infections. Pediatr Infect Dis J 24 457-458.
103. MC Lee, AM Rios, MF Aten, et al. (2004) Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus. Pediatr Infect Dis J 23 123-127.
104. SL Kaplan, KG Hulten, BE Gonzalez, et al. (2005) Three-year surveillance of community-acquired Staphylococcus aureus infections in children. Clin Infect Dis 40 1785-1791.
105. J Wolf, AJ Daley, MH Tilse, et al. (2010) Antibiotic susceptibility patterns of Staphylococcus aureus isolates from Australian children. J Paediatr Child Health 46 404-411.
106. E Lappin and AJ Ferguson (2009) Gram-positive toxic shock syndromes. Lancet Infect Dis 9 281-290.
107. DN Gerding (2009) Clostridium difficile 30 years on: what has, or has not, changed and why? Int J Antimicrob Agents 33(Suppl 1), S2-S8.
108. AP Carter, WM Clemons, DE Brodersen, et al. (2000) Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics. Nature 407 340-348.
109. S Magnet and JS Blanchard (2005) Molecular insights into aminoglycoside action and resistance. Chem Rev 105 477-498.
110. BT Wimberly (2009) The use of ribosomal crystal structures in antibiotic drug design. Curr Opin Investig Drugs 10 750-765.
111. Y Doi, K Yokoyama, K Yamane, et al. (2004) Plasmid-mediated 16S rRNA methylase in Serratia marcescens conferring high-level resistance to aminoglycosides. Antimicrob Agents Chemother 48 491-496.
112. A Gordon and HE Jeffery (2005) Antibiotic regimens for suspected late onset sepsis in newborn infants. Cochrane Database Syst Rev CD004501
113. EI Mtitimila and RW Cooke (2004) Antibiotic regimens for suspected early neonatal sepsis. Cochrane Database Syst Rev CD004495
114. EM Hodson, NS Willis and JC Craig (2007) Antibiotics for acute pyelonephritis in children. Cochrane Database Syst Rev CD003772
115. OM Klibanov, RH Raasch and JC Rublein (2004) Single versus combined antibiotic therapy for gram-negative infections. Ann Pharmacother 38 332-337.
116. GH McCracken Jr (1986) Aminoglycoside toxicity in infants and children. Am J Med 80 172-178.
117. LF Chen and D Kaye (2009) Current use for old antibacterial agents: polymyxins, rifamycins, and aminoglycosides. Infect Dis Clin North Am 23 1053-1075. x
118. LM Baddour, WR Wilson, AS Bayer, et al. (2005) Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 111 e394-e434.
119. DH Mitchell and BP Howden (2005) Diagnosis and management of Staphylococcus aureus bacteraemia. Intern Med J 35(Suppl 2), S17-S24.
120. GR Corey (2009) Staphylococcus aureus bloodstream infections: definitions and treatment. Clin Infect Dis 48(Suppl 4), S254-S259.
121. RE Bryant, K Fox, G Oh, et al. (1992) Beta-lactam enhancement of aminoglycoside activity under conditions of reduced pH and oxygen tension that may exist in infected tissues. J Infect Dis 165 676-682.
122. DE Geller (2009) Aerosol antibiotics in cystic fibrosis. Respir Care 54 658-670.
123. E Ioannidou, Siempos II and ME Falagas (2007) Administration of antimicrobials via the respiratory tract for the treatment of patients with nosocomial pneumonia: a meta-analysis. J Antimicrob Chemother 60 1216-1226.
124. American Society of Health Systems Pharmacists (2009) Aminoglycosides. G McEvoy,(Eds) AHFS Drug Information 2009 Bethesda, MD: American Society of Health-System Pharmacists 65-93.
125. E Nestaas, HJ Bangstad, L Sandvik, et al. (2005) Aminoglycoside extended interval dosing in neonates is safe and effective: a meta-analysis. Arch Dis Child Fetal Neonatal Ed 90 F294-F300.
126. DG Contopoulos-Ioannidis, ND Giotis, DV Baliatsa, et al. (2004) Extended-interval aminoglycoside administration for children: a meta-analysis. Pediatrics 114 e111-e118.
127. G Delgado Jr, MM Neuhauser, DT Bearden, et al. (2000) Quinupristin-dalfopristin: an overview. Pharmacotherapy 20 1469-1485.
128. NJ Johnston, TA Mukhtar and GD Wright (2002) Streptogramin antibiotics: mode of action and resistance. Curr Drug Targets 3 335-344.
129. E Hershberger, S Donabedian, K Konstantinou, et al. (2004) Quinupristin-dalfopristin resistance in gram-positive bacteria: mechanism of resistance and epidemiology. Clin Infect Dis 38 92-98.
130. RC Moellering (2003) Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 138 135-142.
131. B Bozdogan and PC Appelbaum (2004) Oxazolidinones: activity, mode of action, and mechanism of resistance. Int J Antimicrob Agents 23 113-119.
132. RG Wunderink, J Rello, SK Cammarata, et al. (2003) Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 124 1789-1797.
133. AJ Walkey, MR O'Donnell and RS Wiener (2011) Linezolid versus glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials. Chest 139 1148-1155.
134. GE Kenny and FD Cartwright (2001) Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones. Antimicrob Agents Chemother 45 2604-2608.
135. VG Meka, SK Pillai, G Sakoulas, et al. (2004) Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA. J Infect Dis 190 311-317.
136. SL Kaplan, JG Deville, R Yogev, et al. (2003) Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatr Infect Dis J 22 677-686.
137. DL Stevens, B Dotter and K Madaras-Kelly (2004) A review of linezolid: the first oxazolidinone antibiotic. Expert Rev Anti Infect Ther 2 51-59.
138. E Chiappini, C Conti, L Galli, et al. (2010) Clinical efficacy and tolerability of linezolid in pediatric patients: a systematic review. Clin Ther 32 66-88.
139. CJ Chen, CH Chiu, TY Lin, et al. (2007) Experience with linezolid therapy in children with osteoarticular infections. Pediatr Infect Dis J 26 985-988.
140. M Langgartner, A Mutenthaler, N Haiden, et al. (2008) Linezolid for treatment of catheter-related cerebrospinal fluid infections in preterm infants. Arch Dis Child Fetal Neonatal Ed 93 F397.
141. GL Jungbluth, IR Welshman and NK Hopkins (2003) Linezolid pharmacokinetics in pediatric patients: an overview. Pediatr Infect Dis J 22 S153-S157.
142. L Saiman, J Goldfarb, SA Kaplan, et al. (2003) Safety and tolerability of linezolid in children. Pediatr Infect Dis J 22 S193-S200.
143. MX Ho, BP Hudson, K Das, et al. (2009) Structures of RNA polymerase-antibiotic complexes. Curr Opin Struct Biol 19 715-723.
144. SA Darst (2004) New inhibitors targeting bacterial RNA polymerase. Trends Biochem Sci 29 159-160.
145. AJ O’Neill, T Huovinen, CW Fishwick, et al. (2006) Molecular genetic and structural modeling studies of Staphylococcus aureus RNA polymerase and the fitness of rifampin resistance genotypes in relation to clinical prevalence. Antimicrob Agents Chemother 50 298-309.
146. M Xu, YN Zhou, BP Goldstein, et al. (2005) Cross-resistance of Escherichia coli RNA polymerases conferring rifampin resistance to different antibiotics. J Bacteriol 187 2783-2792.
147. N Lounis and G Roscigno (2004) In vitro and in vivo activities of new rifamycin derivatives against mycobacterial infections. Curr Pharm Des 10 3229-3238.
148. WJ Burman, K Gallicano and C Peloquin (2001) Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet 40 327-341.
149. CM Kunin (1996) Antimicrobial activity of rifabutin. Clin Infect Dis 22(Suppl 1), S3-13. discussion S13–4
150. AM Loeffler (1999) Uses of rifampin for infections other than tuberculosis. Pediatr Infect Dis J 18 631-632.
151. C Berger, GE Pfyffer and D Nadal (1996) Treatment of nontuberculous mycobacterial lymphadenitis with clarithromycin plus rifabutin. J Pediatr 128 383-386.
152. G Losurdo, E Castagnola, E Cristina, et al. (1998) Cervical lymphadenitis caused by nontuberculous mycobacteria in immunocompetent children: clinical and therapeutic experience. Head Neck 20 245-249.
153. XF Gao, J Li, ZW Yang, et al. (2009) Rifapentine vs. rifampicin for the treatment of pulmonary tuberculosis: a systematic review. Int J Tuberc Lung Dis 13 810-819.
154. JA Adachi and HL DuPont (2006) Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders. Clin Infect Dis 42 541-547.
155. PC Okhuysen (2005) Current concepts in travelers’ diarrhea: epidemiology, antimicrobial resistance and treatment. Curr Opin Infect Dis 18 522-526.
156. American Academy of (2009) Pediatrics. Tuberculosis. LK Pickering, CJ Baker, DW Kimberlin, SS Long,(Eds) Red Book: 2009 Report of the Committee on Infectious Diseases Elk Grove Village, IL: American Academy of Pediatrics 687-701.
157. PC Appelbaum and PA Hunter (2000) The fluoroquinolone antibacterials: past, present and future perspectives. Int J Antimicrob Agents 16 5-15.
158. MK Bolon (2009) The newer fluoroquinolones. Infect Dis Clin North Am 23 1027-1051. x
159. DC Hooper (2001) Mechanisms of action of antimicrobials: focus on fluoroquinolones. Clin Infect Dis 32(Suppl 1), S9-S15.
160. PG Ambrose, SM Bhavnani and RC Owens Jr (2003) Clinical pharmacodynamics of quinolones. Infect Dis Clin North Am 17 529-543.
161. DC Hooper (2002) Fluoroquinolone resistance among Gram-positive cocci. Lancet Infect Dis 2 530-538.
162. DC Hooper (2001) Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis 7 337-341.
163. A Robicsek, J Strahilevitz, GA Jacoby, et al. (2006) Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nat Med 12 83-88.
164. FDA resource page Food and Drug Administration resources page. http://www.fda.gov/ohrms/dockets/ac/97/transcpt/3349t1.pdf Accessed October 29, 2010 Available at
165. American Academy of Pediatrics Committee on Infectious Diseases. AAP Clinical Report (2011) The use of systemic and topical fluoroquinolones. Pediatrics 128 e1034-e1045.
166. R Grady (2003) Safety profile of quinolone antibiotics in the pediatric population. Pediatr Infect Dis J 22 1128-1132.
167. V Sabharwal and CD Marchant (2006) Fluoroquinolone use in children. Pediatr Infect Dis J 25 257-258.
168. Multicenter, randomized, double blind clinical trial of short course versus standard course oral ciprofloxacin for Shigella dysenteriae type 1 dysentery in children. Pediatr Infect Dis J 21 1136-1141.
169. E Leibovitz, J Janco, L Piglansky, et al. (2000) Oral ciprofloxacin vs. intramuscular ceftriaxone as empiric treatment of acute invasive diarrhea in children. Pediatr Infect Dis J 19 1060-1067.
170. CA Mullen (2003) Ciprofloxacin in treatment of fever and neutropenia in pediatric cancer patients. Pediatr Infect Dis J 22 1138-1142.
171. KF Croom and KL Goa (2003) Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. Drugs 63 2769-2802.
172. R Dagan, A Arguedas and UB Schaad (2004) Potential role of fluoroquinolone therapy in childhood otitis media. Pediatr Infect Dis J 23 390-398.
173. LD Saravolatz and J Leggett (2003) Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones. Clin Infect Dis 37 1210-1215.
174. S Lofmark, C Edlund and CE Nord (2010) Metronidazole is still the drug of choice for treatment of anaerobic infections. Clin Infect Dis 50(Suppl 1), S16-S23.
175. D Pal, S Banerjee, J Cui, et al. (2009) Giardia, Entamoeba, and Trichomonas enzymes activate metronidazole (nitroreductases) and inactivate metronidazole (nitroimidazole reductases). Antimicrob Agents Chemother 53 458-464.
176. HK Leiros, S Kozielski-Stuhrmann, U Kapp, et al. (2004) Structural basis of 5-nitroimidazole antibiotic resistance: the crystal structure of NimA from Deinococcus radiodurans. J Biol Chem 279 55840-55849.
177. KC Lamp, CD Freeman, NE Klutman, et al. (1999) Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin Pharmacokinet 36 353-373.
178. R Nau, F Sorgel and H Eiffert (2010) Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev 23 858-883.
179. KA Sprandel, GL Drusano, DW Hecht, et al. (2006) Population pharmacokinetic modeling and Monte Carlo simulation of varying doses of intravenous metronidazole. Diagn Microbiol Infect Dis 55 303-309.
180. I Brook (2004) Management of anaerobic infection. Expert Rev Anti Infect Ther 2 153-158.
181. J Luther, PD Higgins, PS Schoenfeld, et al. (2010) Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol 105 65-73.
182. GR Greenberg (2004) Antibiotics should be used as first-line therapy for Crohn's disease. Inflamm Bowel Dis 10 318-320.
183. D Shah, MD Dang, R Hasbun, et al. (2010) Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance. Expert Rev Anti Infect Ther 8 555-564.
184. DE Katz and DN Taylor (2001) Parasitic infections of the gastrointestinal tract. Gastroenterol Clin North Am 30 797-815. x
185. JR Schwebke and D Burgess (2004) Trichomoniasis. Clin Microbiol Rev 17 794-803.
186. WR Snodgrass and T Anderson (1937) Sulphanilamide in the treatment of erysipelas. Br Med J 2 1156-1159.
187. WR Snodgrass and T Anderson (1937) Prontosil in erysipelas. Br Med J 2 101-104.
188. JA Libecco and KR Powell (2004) Trimethoprim/sulfamethoxazole: clinical update. Pediatr Rev 25 375-380.
189. E Letko, DN Papaliodis, GN Papaliodis, et al. (2005) Stevens–Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann Allergy Asthma Immunol 94 419-436. quiz 436–8, 456
190. N Levi, S Bastuji-Garin, M Mockenhaupt, et al. (2009) Medications as risk factors of Stevens–Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics 123 e297-e304.
191. JC Craig, JM Simpson, GJ Williams, et al. (2009) Antibiotic prophylaxis and recurrent urinary tract infection in children. N Engl J Med 361 1748-1759.
192. M Adra and KR Lawrence (2004) Trimethoprim/sulfamethoxazole for treatment of severe Staphylococcus aureus infections. Ann Pharmacother 38 338-341.
193. DY Hyun, EO Mason, A Forbes, et al. (2009) Trimethoprim-sulfamethoxazole or clindamycin for treatment of community-acquired methicillin-resistant Staphylococcus aureus skin and soft tissue infections. Pediatr Infect Dis J 28 57-59.
194. JS Bradley (2010) Preferred therapy for specific parasitic pathogens. JS Bradley, JD Nelson,(Eds) 2010–11 Nelson's Pocket Book of Pediatric Antimicrobial Therapy 18th ed Elk Grove Village, IL: American Academy of Pediatrics 94-106.
195. RJ Gaspari, E Dickson, J Karlowsky, et al. (2005) Antibiotic resistance trends in paediatric uropathogens. Int J Antimicrob Agents 26 267-271.
196. I Bollgren (1999) Antibacterial prophylaxis in children with urinary tract infection. Acta Paediatr Suppl 88 48-52.
197. E Wald (2004) Urinary tract infections in infants and children: a comprehensive overview. Curr Opin Pediatr 16 85-88.
198. L Brendstrup, K Hjelt, KE Petersen, et al. (1990) Nitrofurantoin versus trimethoprim prophylaxis in recurrent urinary tract infection in children. A randomized, double-blind study. Acta Paediatr Scand 79 1225-1234.
199. GJ Williams, L Wei, A Lee, et al. (2006) Long-term antibiotics for preventing recurrent urinary tract infection in children. Cochrane Database Syst Rev 3 CD001534
200. BB Lee, JM Simpson, JC Craig, et al. (2007) Methenamine hippurate for preventing urinary tract infections. Cochrane Database Syst Rev CD003265
201. J Elo, S Sarna, K Ahava, et al. (1978) Methenamine hippurate in urinary tract infections in children: prophylaxis, treatment and side effects. J Antimicrob Chemother 4 355-365.
202. JS Bradley, RT Wassel, L Lee, et al. (2009) Intravenous ceftriaxone and calcium in the neonate: assessing the risk for cardiopulmonary adverse events. Pediatrics 123 e609-13.
203. JS Bradley and JD Nelson (Eds) (2012) Antiinfective Therapy for Newborns. Nelson's Pocketbook of Pediatric Antimicrobial Therapy 19th ed Elk Grove Village, IL: American Academy of Pediatrics
204. HE James and JS Bradley (2008) Aggressive management of shunt infection: combined intravenous and intraventricular antibiotic therapy for twelve or less days. Pediatr Neurosurg 44 104-111.
205. Diagnosis and management of acute otitis media. Pediatrics 113 1451-1465.
206. JT Zobell, K Ampofo, J Cash, et al. (2010) High dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients. J Cyst Fibros 9 280-283.
207. Practice parameter: the diagnosis, treatment, and evaluation of the initial urinary tract infection in febrile infants and young children. American Academy of Pediatrics. Committee on Quality Improvement. Subcommittee on Urinary Tract Infection. Pediatrics 103 843-852.
208. JD Nelson, RW Bucholz, H Kusmiesz, et al. (1982) Benefits and risks of sequential parenteral–oral cephalosporin therapy for suppurative bone and joint infections. J Pediatr Orthop 2 255-262.